

## Important Notice Regarding the Annual and Extraordinary Shareholders' Meetings

**Mechelen, Belgium, 20 April 2020** – On 7 April 2020, Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), published its convening notice for the annual and extraordinary shareholders' meetings of the Company that will be held on 8 May 2020. On 9 April 2020, the Belgian Royal Decree no. 4 containing various provisions regarding co-ownership and the law on companies and associations in the framework of the fight against the Covid-19 pandemic was published.

Using the possibility offered by the aforementioned Royal Decree no. 4, and in order to protect the health of individual securities holders and the employees of the Company and others who are responsible for organizing the shareholders' meetings, the Board of Directors of the Company has decided to hold the annual and extraordinary shareholders' meetings behind closed doors without physical presence of the holders of securities of the Company, their proxyholders or others who have the right to attend the shareholders' meetings. This entails that:

- The shareholders of the Company can exercise their voting rights only by way of a **vote by mail or by proxy** to the Chairman of the Board of Directors. Shareholders must provide their signed vote by mail form or proxy form to the Company at the latest on the fourth calendar day prior to the annual and extraordinary shareholders' meetings, i.e. on or **before Monday 4 May 2020 at the latest**.
- Holders of securities of the Company can only exercise their right to ask **questions** related to the items on the agenda of the general shareholders' meetings **in writing**. These written questions must be provided to the Company at the latest on the fourth calendar day prior to the annual and extraordinary shareholders' meetings, i.e. on or **before Monday 4 May 2020 at the latest**. Written questions will be answered in writing and these answers will be published on the website of the Company, in accordance with applicable law.

The modalities of the aforementioned ways to participate in the annual and extraordinary shareholders' meetings are set out in the revised convening notice and relevant forms to vote by mail or by proxy. These documents can be consulted on the [Company's website](#).

The Board of Directors would like to thank the securities holders for their understanding and cooperation.

--- END ---

### More information:

Renate Degrave

Head of Corporate Communications & Investor Relations Biocartis

e-mail [rdegrave@biocartis.com](mailto:rdegrave@biocartis.com)

tel +32 15 631 729

mobile +32 471 53 60 64

[@Biocartis](#) [www.linkedin.com/Biocartis](https://www.linkedin.com/Biocartis)

### About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: [www.biocartis.com](http://www.biocartis.com). Follow us on [Twitter](#): @Biocartis.

*Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla™ trademark and logo are used trademarks owned by Biocartis. This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. Please refer to the product labeling for applicable intended uses for each individual Biocartis product. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.*

**Forward-looking statements**

*Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.*